The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $15.42

Today's change+1.74 +12.72%
Updated June 22 1:17 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $15.42

Today's change+1.74 +12.72%
Updated June 22 1:17 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc Hits New 50-day High

Valeant Pharmaceuticals International Inc is up sharply today, rallying (U.S.)$1.74 or 12.72% to (U.S.)$15.42 and setting a new 50-day high. Over the last five days, shares have gained 27.23% and 6.20% year to date. Shares have underperformed the S&P 500 by 45.77% during the last year.

Key company metrics

  • Open(U.S.) $13.75
  • Previous close(U.S.) $13.68
  • High(U.S.) $15.73
  • Low(U.S.) $13.64
  • Bid / Ask(U.S.) $15.41 / (U.S.) $15.42
  • YTD % change+6.20%
  • Volume49,869,856
  • Average volume (10-day)17,091,153
  • Average volume (1-month)23,379,293
  • Average volume (3-month)22,167,430
  • 52-week range(U.S.) $8.31 to (U.S.) $32.75
  • Beta-0.31
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.80×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.04
Updated June 22 1:17 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.63%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue2,1092,4032,4802,420
Total other revenue--------
Total revenue2,1092,4032,4802,420
Gross profit1,5131,7371,8221,762
Total cost of revenue596665658658
Total operating expense1,9622,2523,3432,340
Selling / general / administrative661665661672
Research & development9693101124
Depreciation / amortization635284807888
Interest expense (income), net operating--------
Unusual expense (income)-274531,11544
Other operating expenses, total1931-45
Operating income147150-86381
Interest income (expense), net non-operating-474-467-470-473
Gain (loss) on sale of assets--------
Other--------
Income before tax-295-360-1,332-377
Income after tax629-512-1,219-304
Income tax, total-924152-113-73
Net income628-515-1,218-302
Total adjustments to net income--------
Net income before extra. items628-515-1,218-302
Minority interest-1-312
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items628-515-1,218-302
Inc. avail. to common incl. extra. items628-515-1,218-302
Diluted net income628-515-1,218-302
Dilution adjustment------0
Diluted weighted average shares351350350345
Diluted EPS excluding extraordinary itemsvalue per share1.79-1.47-3.49-0.88
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share1.77-0.65-1.38-0.78